Phase 4Recruiting
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
- Sponsor
- Marzieh Salehi (Academic or other)
- Enrolment
- 50 planned
- Conditions
- Spinal Cord Injuries; Type 2 Diabetes
- Interventions
- Semaglutide Injectable Product; Placebo
- Ages
- adults, older adults
- Registry
- NCT06706284
From the registry
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Primary outcomes
- Glucose tolerance
- Insulin action